Gu Ye, Zhang Xiaofeng, Yu Weiping, Dong Weifeng
Department of Gastroenterology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P.R. China, 310006.
Hangzhou Hospital & Institute of Digestive Diseases, Hangzhou, Zhejiang, P.R. China, 310006.
J Cancer. 2022 Jan 1;13(2):623-640. doi: 10.7150/jca.57663. eCollection 2022.
SET7/9 is a member of the protein lysine methyltransferase family that methylates both histone 3 lysine 4 (H3-K4) and lysine(s) of other non-histone proteins. In recent years, dis-regulation of SET7/9 were frequently detected in various cancer types and SET7/9-mediated methylation has been recognized as an important mechanism that affects cancer initiation and development through regulation of a series of cellular processes. Here we review the currently identified histone and non-histone protein targets of SET7/9 that are closely correlated with human cancer and the function of SET7/9 in regulating the expression and stability of its protein targets. The review also discusses the putative role of SET7/9 as an oncogene or tumor suppressor in the development of various cancer types and the underlying mechanisms, which may help better evaluate the potential of SET7/9 as a novel candidate for cancer therapy.
SET7/9是蛋白质赖氨酸甲基转移酶家族的成员,可使组蛋白3赖氨酸4(H3-K4)和其他非组蛋白的赖氨酸发生甲基化。近年来,在各种癌症类型中经常检测到SET7/9的失调,并且SET7/9介导的甲基化已被认为是一种重要机制,可通过调节一系列细胞过程来影响癌症的发生和发展。在这里,我们综述了目前已确定的与人类癌症密切相关的SET7/9的组蛋白和非组蛋白靶点,以及SET7/9在调节其蛋白质靶点的表达和稳定性方面的功能。该综述还讨论了SET7/9在各种癌症类型发展中作为癌基因或肿瘤抑制因子的假定作用及其潜在机制,这可能有助于更好地评估SET7/9作为癌症治疗新候选药物的潜力。